SARATOGA, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financial results for the fourth quarter and full year ended December 31, 2025. Recent Highlights Fourth quarter 2025 revenue was $3.9 million, a 13% increase over the fourth quarter of 2024. Full year 2025 revenue was $13.6 million, a 15% increase compared to full year 2024.New accounts grew ...

Core Viewpoint - CapsoVision, Inc. is set to release its fourth quarter and full year 2025 financial results on March 26, 2026, and will host a conference call to discuss these results and provide a corporate update [1]. Group 1: Financial Results Announcement - The financial results will be announced after the market closes on March 26, 2026 [1]. - A conference call and live webcast will take place at 1:30 pm PT / 4:30 pm ET on the same day [1]. Group 2: Company Overview - CapsoVision is a commercial-stage medical technology company focused on advanced imaging and AI-enabled solutions for gastrointestinal disease detection and screening [3]. - The flagship product, CapsoCam Plus®, is a wire-free, panoramic capsule endoscope that provides high-resolution visualization of the small bowel [3]. - The upcoming product, CapsoCam Colon™, features enhanced AI for non-invasive colon imaging and polyp detection [3]. - The company aims to expand its proprietary platform across multiple gastrointestinal indications, including esophageal and pancreatic disorders [3].

Core Insights - CapsoVision, Inc. is participating in the Benchmark 14th Annual Discovery One-on-One Investor Conference on December 4, 2025, in New York City, with key executives attending [1][2] Company Overview - CapsoVision is a commercial-stage medical technology company focused on advanced imaging and AI-enabled solutions for gastrointestinal disease detection and diagnosis [3] - The flagship product, CapsoCam Plus®, is a wire-free, panoramic capsule endoscope that provides high-resolution visualization of the small bowel and supports cloud-based or direct video retrieval [3] - The upcoming product, CapsoCam Colon™, features enhanced AI for non-invasive colon imaging and polyp detection, with plans to expand across multiple gastrointestinal indications [3]

Core Insights - CapsoVision, Inc. reported a total revenue of $3.3 million for Q2 2025, marking a 17% increase compared to Q2 2024, primarily driven by increased sales of CapsoCam Plus capsules [6][9] - The company successfully completed its IPO in July 2025, raising net proceeds of approximately $23.4 million, which will be used to accelerate growth and expand into new indications [3][7][9] - Management highlighted the importance of obtaining FDA 510(k) approval for the AI module in CapsoCam Plus and the continued development of CapsoCam Colon as key growth drivers [4][5] Financial Performance - Total revenue for Q2 2025 was $3.3 million, a 17% increase from $2.8 million in Q2 2024 [6][14] - Gross profit increased to $1.8 million, up 14% from $1.6 million in Q2 2024, with a gross margin of 55% [6][14] - Operating expenses decreased to $6.5 million, down $0.4 million from Q2 2024, mainly due to reduced expenses related to clinical trials [7][14] Operational Highlights - New accounts grew by 75% in Q2 2025 compared to the same quarter in 2024 [9] - CapsoCam Plus has been utilized by over 143,000 patients as of June 30, 2025 [9] - The company submitted a 510(k) notification to the FDA for CapsoCam Colon in June 2025 [9] Future Outlook - The company aims to enhance accuracy and ease physician workload through the integration of AI in its products [4] - CapsoVision plans to advance programs targeting pancreatic cancer and esophageal varices, leveraging its panoramic imaging technology [4][5]